Abstract
Abstract Aim: Although minimal invasive treatment is widely accepted for early stage of gastric cancer (EGC), we still do not have any appropriate risk markers to detect residual neoplasia and some potential of recurrence. We previously reported that aberrant DNA methylation is an early and frequent process in gastric carcinogenesis and could be useful for detection of gastric neoplasia (Gastroenterology 2009, Tumor Biology 2011). Our goal is to verify the potency of our three selected candidate genes (Sox17, MINT25, miR34) as a treatment marker for EGC. Method: We conducted a multicenter, prospective study using selected three candidate genes (Sox17, MINT25 and miR34) by Methylated CpG Island Amplification Microarray (MACAM) based analysis and analyzed the DNA methylation levels before and after endoscopic resection (ER) for EGC using gastric washes. We statistically analyzed sensitivity, specificity and AUC with DNA methylation levels of before / after ER and information of recurrent cases in 2 years. Results: 352 EGC cases were registered and endoscopically removed. 182 cases could followed endoscopically for 2 years (51.7%). Sensitivity, specificity and AUC were as follows. Sox17 (70.0%, 48.1%, 0.646), MINT25 (70.0%, 35.2% 0.555), miR34 (65.0%, 49.4%, 0.578). Conclusion: We have developed a new methodology for gastric cancer detection by DNA methylation in gastric washes. It is easy and useful for early detection of recurrence after endoscopic treatment in GCa patients. Citation Format: Yoshiyuki Watanabe, Ritsuko Oikawa, Hiroyuki Yamamoto, Fumio Itoh. Detection of early gastric cancer with Sox17 DNA methylation analysis of gastric washes. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2764.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have